PA8625401A1 - Aril piperidinas o piperazinas sustituidas con heterociclos de cinco miembros inhibidoras de la mtp - Google Patents

Aril piperidinas o piperazinas sustituidas con heterociclos de cinco miembros inhibidoras de la mtp

Info

Publication number
PA8625401A1
PA8625401A1 PA20058625401A PA8625401A PA8625401A1 PA 8625401 A1 PA8625401 A1 PA 8625401A1 PA 20058625401 A PA20058625401 A PA 20058625401A PA 8625401 A PA8625401 A PA 8625401A PA 8625401 A1 PA8625401 A1 PA 8625401A1
Authority
PA
Panama
Prior art keywords
compounds
piperazinas
aril
replaced
mtp
Prior art date
Application number
PA20058625401A
Other languages
English (en)
Inventor
Lieven Meerpoel
Marcel Viellevoye
Leo Jacobus Jozef Backx
Libuse Jaraskova
Peter Walter Maria Roevens
Der Veken Louis Jozef Elisabeth Van
Joannes Theodorus Maria Linder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8625401A1 publication Critical patent/PA8625401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRESENTE INVENCION ESTA RELACIONADA CON NUEVOS COMPUESTOS DERIVADOS DE ARIL PIPERIDINAS O PIPERAZINAS SUSTITUIDAS CON CIERTOS HETEROCICLOS DE 5 MIEMBROS QUE TIENEN UNA ACTIVIDAD INHIBIDORA DE LA SECRECION DE APOB/MTP Y UNA ACTIVIDAD ANTI-LIPIDEMICA CONCOMITANTE. ADEMAS, LA INVENCION SE REFIERE A METODOS PARA LA PREPARACION DE TALES COMPUESTOS, COMPOSICIONES FARMACEUTICAS QUE INCLUYEN DICHOS COMPUESTOS, COMO ASI TAMBIEN AL USO DE DICHOS COMPUESTOS COMO MEDICAMENTOS PARA EL TRATAMIENTO DE LA HIPERLIPIDEMIA, OBESIDAD Y DIABETES TIPO II. LA INVENCION SE REFIERE ADEMAS A METODOS PARA PREPARAR TALES COMPUESTOS, A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHOS COMPUESTOS, ASI COMO AL USO DE DICHOS COMPUESTOS COMO MEDICAMENTOS PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS, PANCREATITIS, OBESIDAD, HIPERTRIGLICERIDEMIA, HIPER-COLESTEROLEMIA, HIPERLIPIDEMIA, DIABETES Y DIABETES TIPO II.
PA20058625401A 2004-03-10 2005-03-08 Aril piperidinas o piperazinas sustituidas con heterociclos de cinco miembros inhibidoras de la mtp PA8625401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04075771 2004-03-10

Publications (1)

Publication Number Publication Date
PA8625401A1 true PA8625401A1 (es) 2005-09-28

Family

ID=34928108

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058625401A PA8625401A1 (es) 2004-03-10 2005-03-08 Aril piperidinas o piperazinas sustituidas con heterociclos de cinco miembros inhibidoras de la mtp

Country Status (27)

Country Link
US (2) US7504400B2 (es)
EP (1) EP1751131B1 (es)
JP (1) JP4846709B2 (es)
KR (1) KR101171211B1 (es)
CN (1) CN1930143B (es)
AR (1) AR048316A1 (es)
AT (1) ATE414698T1 (es)
AU (1) AU2005219580B2 (es)
BR (1) BRPI0508514A (es)
CA (1) CA2558506C (es)
DK (1) DK1751131T3 (es)
EA (1) EA009455B1 (es)
ES (1) ES2317206T3 (es)
HK (1) HK1103582A1 (es)
IL (1) IL177939A (es)
JO (1) JO2537B1 (es)
MX (1) MXPA06010253A (es)
MY (1) MY142521A (es)
NZ (1) NZ548817A (es)
PA (1) PA8625401A1 (es)
PL (1) PL1751131T3 (es)
PT (1) PT1751131E (es)
SI (1) SI1751131T1 (es)
TW (1) TWI353984B (es)
UA (1) UA85215C2 (es)
WO (1) WO2005085226A1 (es)
ZA (1) ZA200607542B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080048504A (ko) 2005-09-29 2008-06-02 사노피-아벤티스 페닐- 및 피리디닐-1,2,4-옥사디아졸론 유도체, 이의제조방법 및 약제로서의 이의 용도
US8183239B2 (en) * 2005-10-31 2012-05-22 Janssen Pharmaceutica Nv Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
KR20090047458A (ko) 2006-08-08 2009-05-12 사노피-아벤티스 아릴아미노아릴-알킬-치환된 이미다졸리딘-2,4-디온, 이의 제조방법, 이들 화합물을 포함하는 약제 및 이의 용도
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2009079593A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
MX2010008577A (es) 2008-02-06 2010-11-25 Astrazeneca Ab Compuestos.
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
BR112012029227B1 (pt) * 2010-05-19 2020-01-07 Sandoz Ag Processo para a preparação de um composto quiral, composto quiral e uso de um composto
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2852589B1 (en) 2012-05-22 2021-04-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
CA2905751A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
US9663495B2 (en) * 2013-04-25 2017-05-30 Yuhan Corporation Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same
BR112015031291A2 (pt) 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas
EP3010889B1 (de) 2013-06-20 2018-10-03 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
EP3028703B1 (en) 2013-07-29 2019-12-04 Kyowa Kirin Co., Ltd. Piperidine derivatives as wnt signaling inhibitor
WO2015200674A1 (en) * 2014-06-25 2015-12-30 The General Hospital Corporation Neuroactive compounds and methods of using the same
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds
WO2017205709A1 (en) * 2016-05-27 2017-11-30 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of rock
KR20190028763A (ko) 2016-07-12 2019-03-19 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 바이시클릭 화합물
US11161843B2 (en) 2017-01-24 2021-11-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2022187206A1 (en) * 2021-03-01 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof
GB202216960D0 (en) * 2022-11-14 2022-12-28 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826412D0 (en) 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents

Also Published As

Publication number Publication date
ZA200607542B (en) 2008-05-28
ES2317206T3 (es) 2009-04-16
UA85215C2 (uk) 2009-01-12
KR101171211B1 (ko) 2012-08-07
IL177939A (en) 2011-08-31
KR20070014121A (ko) 2007-01-31
TWI353984B (en) 2011-12-11
AR048316A1 (es) 2006-04-19
CN1930143B (zh) 2012-04-04
JP2007527897A (ja) 2007-10-04
AU2005219580A1 (en) 2005-09-15
CA2558506A1 (en) 2005-09-15
AU2005219580B2 (en) 2010-07-08
US7816360B2 (en) 2010-10-19
BRPI0508514A (pt) 2007-08-14
EA009455B1 (ru) 2007-12-28
EP1751131A1 (en) 2007-02-14
CN1930143A (zh) 2007-03-14
EA200601660A1 (ru) 2006-12-29
EP1751131B1 (en) 2008-11-19
MXPA06010253A (es) 2007-02-16
JP4846709B2 (ja) 2011-12-28
PL1751131T3 (pl) 2009-04-30
US20100004263A1 (en) 2010-01-07
MY142521A (en) 2010-12-15
IL177939A0 (en) 2006-12-31
TW200540169A (en) 2005-12-16
DK1751131T3 (da) 2009-03-16
PT1751131E (pt) 2009-02-13
ATE414698T1 (de) 2008-12-15
JO2537B1 (en) 2010-09-05
HK1103582A1 (en) 2007-12-21
WO2005085226A1 (en) 2005-09-15
US20070191383A1 (en) 2007-08-16
SI1751131T1 (sl) 2009-04-30
NZ548817A (en) 2009-04-30
US7504400B2 (en) 2009-03-17
CA2558506C (en) 2012-09-11

Similar Documents

Publication Publication Date Title
PA8625401A1 (es) Aril piperidinas o piperazinas sustituidas con heterociclos de cinco miembros inhibidoras de la mtp
WO2011027222A3 (en) Immunogenic compositions including tlr activity modulators
MX2012002654A (es) Compuestos y composiciones como moduladores de la actividad de tlr.
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
EP1824442A4 (en) PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS DERIVED FROM GARCINIA MANGOSTANA L.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
EA201170512A1 (ru) Композиция для перорального введения
HRP20050103B1 (hr) N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b
BRPI0512357A (pt) composições compreendendo estrÈncio e vitamina d e usos destas
MX2007004765A (es) Compuestos y metodos que modulan la actividad de la trombopoyetina.
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
AR054595A1 (es) Formulaciones/composiciones farmaceuticas de guanfacina apropiadas para forma de administracion diaria en una unica dosis
BRPI0508596A (pt) combinação compreendendo ligante alfa-2-delta
HK1200019A1 (en) Use of a liquid allergy vaccine formulation for oromucosal administration
CL2007002315A1 (es) Compuestos derivados de piridina;composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades o trastornos que comprenden el dolor y/o sindrome del intestino irritable.
BRPI0810773A2 (pt) Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição.
EA200601120A1 (ru) N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
WO2009047779A3 (en) Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
ATE529096T1 (de) Pharmazeutische zusammensetzungen mit bradykinin- antagonisten und hyaluronsäure sowie anwendungen davon
MX2008006476A (es) Composiciones de lipopeptidos.
ATE439841T1 (de) Pharmazeutische zusammensetzungen mit zd6474